Fairwinds
Transforming Innovation into Biotherapeutics
About Us
Medical Innovations
FWB is building a portfolio of late stage pre-clinical and early clinical biotherapeutics through in-licensing and acquisition of novel 3rd party technology.
FWB’s first investment was in MGFB a company focused on exploiting a novel cancer vaccine platform licensed from the Mayo Clinic.
Medical innovations are precious, exciting and come from many different sources including small biotech, academia and individual entrepreneurs. Transforming a good idea into a biotherapeutic product is challenging and capital-intensive endeavor. It requires expertise and capital often not available for startups completing laboratory proof-of-concept.
FairWinds Bio has assembled experts, advisors, service providers, and capital to deploy on late pre-clinical and early clinical assets to accelerate their development into products. The company has deep expertise in oncology but is open to other therapeutic areas as well.
Meet Our Experts
Management Team
Ajit Gill
Founder & CEO
Ajit Gill is past CEO and President of Nektar Therapeutics, when the company grew from a private startup to a public company with 800 employees and a market cap of over $2 billion USD. Mr. Gill graduated from IIT Kanpur with a B. Tech degree in Electrical Engineering and earned an M.S from University of Nebraska and an MBA from University of Western Ontario, Canada. Mr. Gill is currently serving as an advisor for several health care companies in India.
Sanjeev Munshi, PhD, MBA
CBO
Chris Searcy, PharmD
Chief Corporate Development Officer
Chris has 35 years of industry experience working in a variety of settings from large multi-national pharmaceutical companies to early-stage therapeutic start-ups. Chris started his pharmaceutical career at Pfizer and spend 11 years in both technical and business roles. He earned his M.B.A. from the Wharton School at the University of Pennsylvania and has a Doctor of Pharmacy and Bachelor of Science from the University of Minnesota College of Pharmacy.
J. Andrew Sanford, MBA
CFO
Andy has over 30 years experience as a financial leader. Most recently he served as senior advisor to corporate executives and Board of Directors and founder of a financial consulting firm. Previously, served as Equity Capital Markets Group Head at Wells Fargo and was a member of the Investment Banking Operating Committee. Also worked as a Managing Director in Equity Capital Markets for J.P. Morgan Securities and Citigroup prior to that. Andy received a MBA from the Wharton School at the University of Pennsylvania and a BA from Dartmouth College.